This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Dupixent
  • /
  • Evaluation of Dupilumab in Patients With Severe St...
Clinical trial

Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma (VENTURE)

Read time: 3 mins
Last updated:15th Oct 2015
Identifier: NCT02528214

Primary Objective:
- To evaluate the efficacy of dupilumab, compared with placebo, for reducing the use of maintenance oral corticosteroids (OCS) in patients with severe steroid-dependent asthma.

Secondary Objectives:
- To evaluate the safety and tolerability of dupilumab.
- To evaluate the effect of dupilumab in improving patient-reported outcomes.
- To evaluate dupilumab systemic exposure and the incidence of treatment-emergent antidrug antibodies.

Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Severe Steroid Dependent Asthma
Estimated Enrollment: 180
Actual Study Start Date: October 15, 2015
Estimated Study Completion Date: November 15, 2017
Primary Completion Date: September 20, 2017 (Final data collection date for primary outcome measure)

- Experimental:
- Placebo Comparator: Placebo

Category Value
Date last updated at source 2017-10-26
Study type(s) Interventional
Expected enrolment 180
Study start date 2015-10-15
Estimated primary completion date 2017-09-20

View full details